secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001104659-24-038744
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock
--------------------------------------------------------------------------------

- Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.
- Potential milestone payments up to $37.5M upon development and commercial milestones.
- BMS license assumed: up to $142M clinical/regulatory milestones + $50M commercial milestones per product; royalties high single to low teen % on net sales.
- CEO states AL102 may establish new standard of care for desmoid tumors; preclinical programs advancing to Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/tm249326d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer